Message #46 From:
NewsBot Date: March 22, 2007 09:15:00 AM
NEOP News Dutton Associates Announces Investment Opinion: Neoprobe Upgraded to Strong Speculative Buy Rating in Update Report by Dutton Associates
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Dutton Associates updates its coverage of Neoprobe Corporation (OTCBB:NEOP), upgrading its rating from Speculative Buy to Strong Speculative Buy and establishing a 12-month price target of $1.30. The 18-page report by Dutton Associates senior analyst Dennis C. Fischer, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, and Knobias and other leading financial portals.
Neoprobe Corporation engages in the development and commercialization of surgical and diagnostic products. We believe Lymphoseek®, a proprietary radiopharmaceutical intended for use in biopsy procedures for the detection of cancer cells in lymphatic tissues in a variety of tumor types, including breast, melanoma, prostate, gastric and colon cancers, provides substantial potential and will be the impetus for the Company’s emergence into profitability in 2009. Currently in Phase II clinical trials, Lymphoseek has clear advantages over existing compounds on the market that are being used off label for this indication.
About Dutton Associates
Dutton Associates is one of the largest independent investment research firms in the U.S. Its 27 senior analysts are primarily CFAs, and have expertise in many industries. Dutton Associates provides continuing analyst coverage of 110 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.
The current cost of enrollment in our one-year continuing research program is US $35,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $70,000 from the Company for 10 Research Reports with coverage commencing on 7/26/04. The Firm does not accept any equity compensation. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.
